Infection protection with XEMBIFY
In a clinical study, people taking XEMBIFY saw improvement in their symptoms of PI and the impact PI had on their lives. Within a year, people taking XEMBIFY experienced:
Eligible XEMBIFY patients may pay as little as $0 copay*
Eligible XEMBIFY patients may pay as little as $0 copay*
XEMBIFY is a subcutaneous immune globulin (SCIG) replacement therapy used to treat primary humoral immunodeficiency disease (PI) in patients 2 years of age and older.
Learn why XEMBIFY could be a good choice for you.
Learn more about savings and support for XEMBIFY.
*Subject to terms and conditions.
In a clinical study, people taking XEMBIFY saw improvement in their symptoms of PI and the impact PI had on their lives. Within a year, people taking XEMBIFY experienced:
0 serious bacterial infections 1*†
Fewer than 3 days of missed work/school due to infections 1
0 hospitalizations due to infections 1†
*One patient reported sepsis due to an animal bite, an event deemed unrelated to the treatment.
†Rate per subject-year: 0.049.
Steady Protection
In a clinical trial, all patients maintained antibody levels above the commonly accepted level that helps fight infections.1
Maximum purity
Unique manufacturing process produces a product with a maximum percentage of IgG.2
Hear Joanne, a retired nurse with PI, describe her experience with XEMBIFY and how she learned about self-infusion.
As with any medication, there is a possibility of side effects. The most common side effects in a clinical study with PI patients who received XEMBIFY were3:
Discuss any side effects that concern you with your healthcare provider. You can also view the XEMBIFY full Prescribing Information, which is available to healthcare professionals.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
If you have any questions about XEMBIFY, you can view the XEMBIFY FAQs to learn more or call
XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product.
Infusing XEMBIFY
Learn about infusing XEMBIFY with this step-by-step video.
Savings and Support
Learn more about Xembify Connexions™ for strong support from the start.
Resources
Learn how to register for XEMBIFY speaker programs, get educational resources, and find PI patient organizations.
What is XEMBIFY®?
XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
XEMBIFY is for subcutaneous administration only.
Important Safety Information
WARNING: THROMBOSIS
Who should not use XEMBIFY?
What are possible serious side effects of XEMBIFY?
What are other possible side effects of XEMBIFY?
Please see full Prescribing Information for XEMBIFY.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Terms to Know
PI, primary humoral immunodeficiency disease
SCIG, subcutaneous immune globulin
References